KU Eye physicians performing cutting-edge, basic, clinical and applied research in ophthalmology and vision science


Faculty as Principle Investigator

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or ocular Hypertension - Principle Investigator: Neeti Alapati, MD; Co-investigator: John Sutphin, MD

DREAM Study - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease - Principle Investigator: John Sutphin, MD. No longer enrolling.

INTACS Prescription Inserts for Keratoconus--Humanitarian Use Device - Principle Investigator: John Sutphin, MD

IVCM:  In vivo confocal microscopy prospective evaluation of morphologic features of uveitis and keratitis - Principle Investigator: John Sutphin, MD; Co-Investigator: William Godfrey, MD.

Orbital Mucormycosis: A Retrospective Review - Principle Investigator: Jason Sokol, MD; Co-Investigator: Michael Gilbert, MD

Protective Lenswear for Patients with Monocular Vision - Principle Investigator: William Abraham White, MD; Co-Investigators: Jonathan Manhard, MD, Merryl Terry, MD, Michael Gilbert, MD

Space Occupying Lesions of the Orbit - Chart Review - Principle Investigator: Jason Sokol, MD; Co-Investigators: Joshua Jones, MD, Anjulie Quick, MD

Strabismus Surgery Following Orbital Decompression in Type 1 and Type 2 Grave Thyroid Eye Disease - Principle Investigator: Jason Sokol, MD

Wet Lab

Faculty as Sub-Investigator

A Multicenter, Randomized, Investigator- and Subject-Blind Placebo-Controlled Treatment Sequence Study Evaluating the Safety, Tolerability and Efficacy of UCB 7665 in Subjects with Moderate to Severe Myasthenia Gravis Phase 2A - Principle Investigator: Mazen Dimachkie, MD; Sub-Investigators: Radwan Ajlan, MD, Neeti Alapati, MD, John Sutphin, MD,  W. Abraham White, MD, Thomas Whittaker, MD

A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafaneib + Binimetinib + Cetuximb in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer - Principle Investigator: Raed al-Rajabi, MD; Sub-Investigators: Neeti Alapali, MD, Anjulie Quick, MD, Jason Sokol, MD, John Sutphin, MD, W Abraham White, MD  

An Open-Label Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects with Advanced Solid Tumors Known to Express C4.4.a - Principle Investigator: Chao Huang, MD; Sub-Investigators: Dirck DeKeyser, OD, William Godfrey, MD, Jason Sokol, MD, John Sutphin, MD, W Abraham White, MD, Thomas Whittaker, MD

A Phase III Double-blind, Randomized, Placebo-controlled, Multicenter Study of VM202 in Painful Diabetic Peripheral Neuropathy - Principle Investigator: Mazen Dimachkie, MD; Sub-investigators: Dirck DeKeyser, OD, W. Abraham White, MD

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications - Principle Investigator: Stephen Williamson, MD; Sub-investigators: John Sutphin, MD and W. Abraham White, MD

A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Choloangiocarcinoma Including FGFR2 Translocations who Failed Previous Therapy - Principle Investigator: Raed Al-Rajabi, MD; Sub-investigators: Neeti Alapati, MD, Anjulie Quick, MD, John Sutphin, MD, W. Abraham White, MD and Thomas Whittaker, MD

A Phase III Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation - Principle Investigator: Tara Lin, MD; Sub-investigator: John Sutphin MD  

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in mild Alzheimer's Disease Dementia - Principle Investigator: Jeffrey Burns, MD; Sub-Investigator:s Dirck DeKeyser, OD, Jason Sokol, MD, John Sutphin, MD

A Randomized, Open-label, Phase II Study of Denintuzumab Mafodotin (SGN CD19A) Plus rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy versus RICE in the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) who are Candidates for Autologous Stem Cell Transplant - Principle Investigator: Anurag Singh, MD; Sub-investigators: Neeti Alapati, MD, William Godfrey, MD, Anjulie Quick, MD, Jason Sokol, MD, John Sutphin, MD, Thomas Whittaker, MD  

A Randomized Phase II Trial of Myeloablative versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma - Principle Investigator: Leyla Shune, MD; Sub-investigators: Dirck DeKeyser, OD,  W Abraham White, MD, Thomas Whittaker, MD 

A Randomized Phase III Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression versus Ipilimuab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma - Principle Investigator: Gary Doolittle, MD; Sub-investigator: Neeti Alapati, MD, William Godfrey, MD and Anjulie Quick, MD

A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplifcation (Intellance 1) - Principle Investigator: Michael Salacz, MD; Sub-investigators: Neeti Alapati, MD, Anjulie Quick, MD, John Sutphin, MD, W Abraham White, MD and Thomas Whittaker, MD  

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 - Principle Investigator: Peter Van Veldhuizen, MD; Sub-investigators: Neeti Alapati, MD, John Sutphin, MD and W Abraham White, MD.

Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders - Principle Investigator: Sharon Lynch, MD; Sub-investigators:  W. Abraham White, MD and Thomas Whittaker, MD.

Relapsing-Remitting Multiple Sclerosis Study Evaluating Safety and Efficacy of Two Doses of Fingolimod versus Copaxone - Principle Investigator: Sharon Lynch, MD; Sub-investigators: Dirck DeKeyeser, OD, Thomas Whittaker, MD

Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib - Principle Investigator: Abdulraheem Yacoub, MD; Sub-investigators: Dirck DeKeyser, OD and W. Abraham White, MD.

The Surpass Intracranial Aneurysm EmbolizatioN System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms - Principle Investigator: Koji Ebersole, MD; Sub-investigator: W. Abraham White, MD

 For more information on research projects, please contact: 913-588-0105

Last modified: Oct 26, 2017